Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anticancer agent that selectively induces apoptosis in a variety of cancer cells by interacting with death receptors DR4 and DR5. TRAIL can also bind to decoy receptors (DcR1, DcR2, and osteoprotegerin receptor) that cannot induce apoptosis. Different tumor types respond either to DR4 or to DR5 activation, and chemotherapeutic drugs can increase the expression of DR4 or DR5 in cancer cells. Thus, DR4 or DR5 receptor-specific TRAIL variants would permit new and tumorselective therapies. Previous success in generating a DR5-selective TRAIL mutant using computer-assisted protein design prompted us to make a DR4-selective TRAIL variant. Technically, the design of DR4 receptor-selective TRAIL variants is considerably more challenging compared with DR5 receptorselective variants, because of the lack of a crystal structure of the TRAIL-DR4 complex. A single amino acid substitution of Asp at residue position 218 of TRAIL to His or Tyr was predicted to have a favorable effect on DR4 binding specificity. Surface plasmon resonance-based receptor binding tests showed a lowered DR5 affinity in concert with increased DR4 specificity for the designed variants, D218H and D218Y. Binding to DcR1, DcR2, and osteoprotegerin was also decreased. Cell line assays confirmed that the variants could not induce apoptosis in DR5-responsive Jurkat and A2780 cells but were able to induce apoptosis in DR4-responsive EM-2 and ML-1 cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anticancer agent that selectively induces apoptosis in a variety of cancer cells by interacting with death receptors DR4 and DR5. TRAIL can also bind to decoy receptors (DcR1, DcR2, and osteoprotegerin receptor) that cannot induce apoptosis. Different tumor types respond either to DR4 or to DR5 activation, and chemotherapeutic drugs can increase the expression of DR4 or DR5 in cancer cells. Thus, DR4 or DR5 receptor-specific TRAIL variants would permit new and tumorselective therapies. Previous success in generating a DR5-selective TRAIL mutant using computer-assisted protein design prompted us to make a DR4-selective TRAIL variant. Technically, the design of DR4 receptor-selective TRAIL variants is considerably more challenging compared with DR5 receptorselective variants, because of the lack of a crystal structure of the TRAIL-DR4 complex. A single amino acid substitution of Asp at residue position 218 of TRAIL to His or Tyr was predicted to have a favorable effect on DR4 binding specificity. Surface plasmon resonance-based receptor binding tests showed a lowered DR5 affinity in concert with increased DR4 specificity for the designed variants, D218H and D218Y. Binding to DcR1, DcR2, and osteoprotegerin was also decreased. Cell line assays confirmed that the variants could not induce apoptosis in DR5-responsive Jurkat and A2780 cells but were able to induce apoptosis in DR4-responsive EM-2 and ML-1 cells.
Computational protein design methods have been successfully employed to redesign several protein-protein interactions (1-4), but they have as yet hardly been applied to redesign target binding preferences of therapeutic proteins. Computational protein design methods allow the rational design of tailor-made protein therapeutics by modifying the binding characteristics of the protein, for example to reduce target binding promiscuity or to design novel mechanisms of activity.
Tumor necrosis factor (TNF) 4 -related apoptosis-inducing ligand (TRAIL) is a potential protein therapeutic currently attracting great interest because of its anti-cancer activity. TRAIL selectively induces apoptosis in tumor cells in vitro and in vivo by a death receptor-mediated process. Unlike other apoptosis-inducing TNF family members, soluble TRAIL appears to be inactive against normal healthy tissue (5). TRAIL shows a high degree of promiscuity as it binds to five cognate receptors as follows: DR4 (TRAIL-R1) and DR5 (TRAIL-R2) and three decoy receptors, DcR1 (TRAIL-R3), DcR2 (TRAIL-R4), and osteoprotegerin (OPG) (6) . Upon binding to TRAIL, DR4 and DR5 receptors recruit Fas-associated death domain (7) (8) (9) , which leads to recruitment and activation of caspase-8 and -10 triggering apoptosis (10 -13). DcR1 does not contain a death domain, and DcR2 contains a truncated death domain, and thus, binding of TRAIL to these receptors does not induce apoptosis. In contrast, these decoy receptors could prevent apoptosis by sequestering available TRAIL or by interfering with the formation of a TRAIL-DR4 or -DR5 signaling complex (14) .
Use of DR4-selective variants could permit better tumorspecific therapies through escape from the decoy receptor-mediated antagonism, resulting in a higher efficacy with possibly less side effects as compared with wtTRAIL (15) (16) (17) (18) . Receptors DR4 and/or DR5 were shown to be up-regulated after treatment with DNA-damaging chemotherapeutic drugs, and the response to TRAIL-induced apoptosis was significantly increased (6, 19) . Previously, we described the design of DR5-selective TRAIL variants (20) . These variants showed an increased affinity for the DR5 receptor and decreased affinities for the DR4 and decoy receptors. A recent study demonstrated that primary cells isolated from patients with chronic lymphocytic leukemia and mantle cell lymphoma were almost exclusively sensitive to DR4-mediated apoptosis (21, 22) . The existence of certain cancer cells only responding to DR4-mediated apoptosis (20) and favorable results obtained with agonistic anti-DR4 antibodies (23) prompted us to design a DR4-selective TRAIL variant.
Because wild-type TRAIL has higher affinity for DR5 than DR4 (20, 24) , the design of an effective DR4-selective TRAIL variant should preferably aim at both an enhanced affinity for DR4 and at decreased affinities for DR5 and decoy receptors. Consequently, it is essential to combine a positive design strategy strengthening the interactions between TRAIL and DR4 with a negative strategy that designs mutations disrupting interactions between TRAIL and the other receptors. Generally, it is less demanding to only disrupt an existing interaction (or create an unfavorable one) by an amino acid substitution than to combine this with the creation of a new favorable interaction. A high quality structural model describing all the relevant interactions between the interacting partners is therefore of paramount importance. As the only crystal structure available is that of the TRAIL-DR5 complex, the design of a DR4-selective variant critically depends on the quality of the homology model of the TRAIL-DR4 complex. We demonstrate here that the design of DR4-specific rhTRAIL variants is possible using homology modeling and computational protein design.
EXPERIMENTAL PROCEDURES
All reagents were of analytical grade unless specified otherwise. Isopropyl ␤-D-1-thio-galactoside, ampicillin, and dithiothreitol were from Duchefa (Haarlem, The Netherlands). Chromatographic columns and media were from Amersham Biosciences. Restriction enzymes were purchased from New England Biolabs. Recombinant TRAIL-receptor Ig fusion proteins formulated with bovine serum albumin were ordered from R & D Systems. All other chemicals were from Sigma. All buffers used in SPR, ELISA, and biological activity assays were of physiological pH and ionic strength.
Modeling of TRAIL-Receptor Complexes-At present only the crystal structure of TRAIL in complex with the DR5 receptor is known. The template selected was Protein Data Bank code 1D4V (25); the structure was at 2.2 Å resolution and of monomeric human TRAIL in complex with the ectodomain of DR5 (TRAIL-R2) receptor. The homotrimer was generated using the protein quaternary structure server from the EBI, having the symmetry coordinates in the Protein Data Bank file. From the sequence alignment of the different TRAIL receptors (26) , it is observed that the receptor cysteine-rich domains (CRDs) involved in the interaction with TRAIL (CRD2 and CRD3) are highly conserved, with the exception of the soluble receptor OPG. Indeed, when compared with DR5, the sequence identity of any other membrane-attached TRAIL receptor is higher than 50% in each case, and there are neither insertions nor deletions in the sequence (with the exception of a glycine deletion in the middle of the CRD3 in DcR1). In addition, all the cysteines involved in the formation of internal disulfide bridges are conserved and share the same sequence position. Thus it is possible to build homology models of all TRAIL receptors except for OPG.
The homology model of TRAIL-DR4 was built using the protein design capabilities of FoldX. The DR5 amino acid residues were mutated into the corresponding DR4 amino acids, and subsequently, all amino acid side chain interactions were optimized to accommodate TRAIL and receptor residues to their new interface.
Computational Design of the Mutants-A detailed description of the empirical force field FoldX (version 2.6) is available elsewhere (27, 28) and on line. Briefly, this force field calculates the free energy of unfolding (⌬G) of a target protein or protein complex combining the physical description of the interactions with empirical data obtained from experiments on proteins. Force field components (polar and hydrophobic solvation energies, van der Waals interactions, van der Waals clashes, H-bond energies, and electrostatics in the complex and its effects on the k on and backbone and side chain entropies) were calculated evaluating the properties of the structure, such as its atomic contact map, the accessibility of its atoms and residues, the backbone dihedral angles, the H-bond network, and the electrostatic network of the protein. Water molecules making two or more H-bonds with the protein were also taken into account (29) .
FoldX was able to perform amino acid mutations and simultaneously accommodate the new residues and its surrounding amino acids (28) . FoldX first mutates the selected position to alanine and annotates the side chain energies of the neighbor residues. Then it mutates this alanine to the selected amino acid and recalculates the side chain energies of the same neighboring residues. Those that exhibit an energy difference are then mutated to themselves to see if another rotamer will be more favorable.
This procedure was also used to reconstruct the binding interface of TRAIL in complex with the modeled DR4 receptor; to repair residues with bad torsion angles, residues having bad van der Waals clashes or to build up the putative interactions between TRAIL and the modeled receptor. the most optimal amino acid conformation was chosen using rotamer substitution (see above). The crystal structure of TRAIL in complex with the DR5 receptor was also refined this way.
Site-directed Mutagenesis, Expression, and Purification of Selectivity Mutants-A cDNA corresponding to human soluble TRAIL (amino acids 114 -281) was cloned in pET15B (Novagen) using NcoI and BamHI restriction sites. Mutants were constructed by PCR as described before (30) . Homotrimeric TRAIL proteins were purified using a three-step purification as described previously (30) . Analytical gel filtration and nonreducing gel electrophoresis confirmed that rhTRAIL WT, D218H, and D218Y are trimeric molecules; they do not form higher degree aggregates and do not contain inter-chain disulfide bridges.
Determination of Receptor Binding-Binding experiments were performed using a surface plasmon resonance-based biosensor Biacore 3000 (Biacore AB, Uppsala, Sweden) at 37°C. DR4-Ig, DR5-Ig, DcR1-Ig, DcR2-Ig, and OPG-Ig receptor chimeras were captured at a 35 l/min flow rate using a protein A (Sigma)-modified CM5 sensor chip (Biacore). Receptors chi-meras were captured at a level of ϳ500 -800 response units. Purified rhTRAIL WT and rhTRAIL variants were injected 3-fold at concentrations ranging from 250 to 2 nM at 70 l/min flow rate using HBS-EP (Biacore) as running and sample buffer. Binding of ligands to the receptors was monitored in real time. Between injections the protein A sensor surface was regenerated using a 30-s pulse of 10 mM glycine, pH 2.0. The resonance signal measured on the reference cell (containing protein A only) was subtracted from the signal measured on the experimental flow cell. All sensorgrams were corrected for buffer injection. To obtain pre-steady state data that represent proper high affinity complex formation, and assuming the initial fast off-rate to represent lower affinity complexes, the response at each concentration was recorded 30 s after the end of the injections. The response data as a function of TRAIL concentration were fitted by using a four-parameter equation to give an apparent affinity constant.
Selectivity of the variants toward the DR4 receptor was also assessed using a competitive ELISA experiment as described before (20) . In short, 10 ng/well rhTRAIL WT or receptor-selective variants were preincubated with 0 -500 ng/well DR4 or DR5-Ig for 30 min. Preincubated solutions were added to microtiter plates coated with DR4-Ig. After washing away unbound sample, bound rhTRAIL WT or variants were detected with a polyclonal goat anti-TRAIL antibody (R & D Systems) followed by a horseradish peroxidase-conjugated swine anti-goat antibody (BIOSOURCE) using the one-step turbo 3,3Ј,5,5Ј-tetramethylbenzidine-ELISA (Pierce) as detection reagent. Absorbance was measured at 450 nm. Binding of the receptor-selective variants to immobilized DR4-Ig at various concentrations of soluble competitor was calculated relative to the value measured in the absence of soluble receptor.
Biological Activity, Cell Line, and Treatment-A2780, ovarian adenocarcinoma cells were maintained in Dulbecco's modified Eagle's medium, whereas Jurkat T cell leukemia, ML-1 acute myeloid leukemia, and EM-2 chronic myelogenous leukemia cell lines were maintained in RPMI 1640 medium, both supplemented with 10% fetal calf serum, 50 units/ml penicillin, 5 mg/ml streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate in a humidified incubator, 37°C, 5% CO 2 environment.
Annexin V Staining-Cells were seeded the day before the experiment at a density of 3.5 ϫ 10 5 , 5 ϫ 10 5 , and 3 ϫ 10 5 cells/ml in 24-well plates (0.5 ml/well) for A2780, Jurkat, ML-1 and EM-2 cell types, respectively. 10 -250 ng/ml rhTRAIL WT, D269HE195R, D218H, or D218Y was added to the cells and incubated for 24 h. FLAG-tagged TRAIL (Alexis) was preincubated with 1 g/ml enhancer for 20 min (cross-linking) before adding it to Jurkat cell cultures in a concentration between 10 and 250 ng/ml. A2780 cells were trypsinized gently, and the cells were allowed to recover for 10 min with gentle shaking at 37°C before pelleting by centrifugation. Jurkat, ML-1, and EM-2 cells were transferred into Eppendorf tubes and spun down. Cell pellets were resuspended in 50 l of annexin V incubation buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) containing 6 l of annexin V-fluorescein isothiocyanate (IQ Corp.) for 15 min on ice. The reaction was stopped by adding 300 l of fresh incubation buffer, and the samples were analyzed immediately using a FACSCalibur flow cytometer (BD Biosciences). Results were expressed as percentage of annexin V-positive cells.
RESULTS
Selectivity Design-For the design of a DR4-selective TRAIL variant, the procedure previously used for the design of DR5-selective TRAIL variants was used (20) . In short, the receptor binding interface of TRAIL was screened for single amino acid substitutions that increase the affinity for the DR4 receptor (decreasing interaction energy (⌬⌬G i )) or decreasing affinity for DR5. For the TRAIL-DR4-receptor complex, a homology model consisting of TRAIL in complex with CRD2 and -3 of DR4 was constructed based on the TRAIL-DR5-receptor com- plex. For the TRAIL-DR5-receptor complex, the 1D4V crystal structure was used (25) . CRD2 and -3 of DR4 show a considerable degree of sequence identity with DR5 (ϳ50%), and the alignment contains no insertions or deletions (not shown); consequently, it was decided to use a model with an identical amino acid backbone conformation as TRAIL-DR5. FoldX was used to build the TRAIL-DR4 model by mutating DR5 amino acid residues into the corresponding DR4 amino acids, followed by optimization of all amino acid side chain interactions (27, 28) . In Fig. 1 , electrostatic charges mapped on the solvent-accessible surface of TRAIL, DR5, and the DR4 model are depicted. It can be seen that the surface electrostatics of TRAIL and DR5 are more complementary with each other than the surface electrostatics of TRAIL and DR4. The accuracy of the models and the force field was tested using the affinity data derived from the alanine scanning of rhTRAIL as performed by Hymowitz et al. (31) . The predictions of the energy change in the complex formation correlate with the changes in the dissociation constants measured (data not shown) (20) . This implies that the above method can reliably predict mutations in the binding interface that would alter ligand-receptor interaction.
The FoldX design process (see "Experimental Procedures") proposed several positions in the receptor-binding interface of TRAIL and (single) amino acid substitutions enhancing DR4 selectivity. One of the proposed mutations, K201R, was already present in a sextuple mutant selected by Kelley et al. (32) using phage display, underlining the correctness of the DR4 model. In addition, new amino acid substitutions were predicted that have not been described before. Of these, the D218Y and D218H mutations were predicted to result in the highest increase in DR4 selectivity by maintaining or improving the interaction with DR4 and decreasing the interaction with DR5 . To obtain pre-steady state data that represent proper high affinity complex formation, and assuming the initial fast off-rate to represent lower complexes, the response at each concentration was recorded 30 s after the end of the injections. Receptor binding was calculated relative to the response of rhTRAIL WT at 250 nM. Competition ELISA used DR4-Ig as competitor (C) or soluble DR5-Ig as competitor (D). rhTRAIL WT or variants were preincubated with 0 -500 ng/well DR4 or DR5 during 30 min. Preincubated solutions were added to microtiter plates coated with DR4-Ig. Binding of the selective variants at various concentrations of soluble receptor toward the immobilized DR4-Ig was calculated relative to the value measured on the presence of 0 ng/well of soluble receptor. (Fig. 2) . To assess the effect of pH on receptor binding of D218H, calculations were performed while introducing a charged, neutral, and partially charged histidine at position 218 to reflect acidic, basic, and physiological pH environments, respectively. As shown in Fig. 2 , the decreased affinity of D218H for DR5 is partially accounted for by electrostatic repulsion as the ⌬⌬G i increases from 1.2 to 2.0 kcal/mol when going from a neutral to a charged histidine. In contrast, the affinity for DR4 is not dependent on pH (Fig. 2) . The D218A mutation has been described previously by Hymowitz et al. (31) to reduce the affinity for DR4 (1.3-fold) and, more pronounced, for DR5 (1.9-fold). FoldX also predicts that this variant has a lowered affinity for DR5 (Fig. 2) . The D218H and D218Y rhTRAIL mutants were made, produced, and purified as described before (20, 30) .
Receptor Binding-Binding of the purified ligands to protein A-immobilized DR4-Ig and DR5-Ig receptor chimeras was assessed in real time using SPR. Receptor binding curves were recorded using rhTRAIL concentrations ranging from 2 to 250 nM at 37°C (Fig. 3A and B) . Apparent dissociation constants were calculated from pre-steady state response values (Table 1) . Although the apparent dissociation constant (K d ) for DR4 of both variants remained unchanged when compared with rhTRAIL WT, both variants showed a 3-3.5-fold increase in their apparent dissociation constant for DR5 (Table 1) . Inspection of the sensorgrams recorded at 37°C for DR4 and DR5 revealed that the k off for rhTRAIL WT was very low (supplemental Fig. 1, A and B, left) . On the other hand, both D218H and D218Y variants showed an initial increased off-rate, which in the case of binding to DR4 (supplemental Fig. 1A , middle, right) was much smaller than the off-rate at the DR5 receptor (supplemental Fig. 1B, middle, right) .
To assess the selectivity of D218H and D218Y toward the DR4 receptor in the presence of the DR5 receptor, a competitive ELISA experiment was performed. Although soluble DR4-Ig was equally efficient in reducing the binding of both rhTRAIL and the Asp-218 variants toward immobilized DR4-Ig by 50%, soluble DR5-Ig was more than 9-fold less efficient in achieving a 50% reduction in binding toward immobilized DR4 for the Asp-218 variants than for rhTRAIL WT (Fig. 3, C and  D) . These results indicate that D218H and D218Y preferentially bind to the DR4 receptor when both DR4 and DR5 receptors are present.
Binding affinities for both variants to the decoy receptors DcR1, DcR2, and OPG were also measured by SPR (Fig. 4, B and  C) . D218H and D218Y showed a 2-3-fold reduction in apparent K d for immobilized DcR2-Ig, mainly because of an increased off-rate. The reduction in binding to immobilized DcR1-Ig was more modest. On both receptors, the increase in off-rate was largest for D218Y (supplemental Fig. 2, A and B) . Binding to immobilized OPG-Ig showed a more complex behavior. Although at concentrations above 125 nM the initial off-rate was still increased for both variants, the maximum level of binding, in particular for D218H, was comparable with the wild-type level. However, at concentrations below 125 nM, DcR2-Ig (B) , or to OPG-Ig (C). Curve fitting was generated from data points derived from the sensorgrams as described in Fig. 3 . Receptor binding is calculated relative to the response of TRAIL at 250 nM. binding of both D218H and D218Y to immobilized OPG-Ig was significantly reduced because of a large increase in k off (supplemental Fig. 2C ). In summary, these results show that the D218Y and D218H mutations provide DR4 selectivity by decreasing the affinity for DR5, DcR2, and OPG while leaving the affinity for DR4 unchanged.
Biological Activity-To test the ability of D218Y and D218H variants to selectively bind and activate DR4, A2780, Jurkat, ML-1, and EM-2 cells were treated with this variant. Previously, it was established that A2780 and Jurkat cells express only DR5 on their surface and hence are only sensitive toward TRAILinduced apoptosis mediated by DR5 (20, 32) . In contrast, ML-1 and EM-2 cells are mainly sensitive toward TRAIL-induced apoptosis mediated by DR4 (supplemental Fig. 3 ) (20) . In Jurkat cells D218Y and D218H showed almost no apoptosis inducing activity (Ͻ10%) up to the highest measured concentration of 500 ng/ml compared with rhTRAIL (24% at 500 ng/ml). The restricted apoptosis-inducing ability of D218H and D218Y in Jurkat cells was even more evident when it was compared with the apoptosis inducing activity of cross-linked FLAG-tagged TRAIL (80% at 500 ng/ml) (Fig. 5A) , a more potent inducer of apoptosis in this particular cell line (33) .
In the second DR5-sensitive cell line A2780, the DR5-selective TRAIL variant D269H/E195R displayed the highest apoptosis inducing activity. D218H and D218Y showed significantly lower activity when compared with both the DR5-selective variant and rhTRAIL WT (Fig. 5B) .
In contrast, in the DR4-responsive cell lines, EM-2 and ML-1, D218H, and D218Y variants were able to efficiently induce apoptosis at concentrations above 100 ng/ml (Fig. 5,  C and D) , whereas the DR5-selective variant D269H/E195R essentially lacked apoptosis inducing activity under these conditions. D218H showed higher apoptosis inducing activity in comparison with D218Y, but both variants were less active than rhTRAIL WT. With regard to potential DR4-selective behavior, it is important to correct for this lower agonistic activity. In the DR5-responsive A2780 cell line at a concentration of 250 ng/ml, less than 10% apoptosis is induced by the best performing DR4-selective variant D218H, whereas both rhTRAIL WT and D269H/E195R induced between 20 and 30% apoptosis. In contrast, both rhTRAIL WT and the D218H variant were able to efficiently induce apoptosis (85 and 80%, respectively) in the DR4-responsive cell line EM-2 at this concentration, whereas the DR5-selective variant induced only 34% apoptosis. This is illustrated in Fig. 6 for rhTRAIL WT, D218H, and the DR5-selective variant D269H/E195R. Taken together, these results confirm that the D218H and D218Y variants induce apoptosis preferentially via DR4.
DISCUSSION
TRAIL interacts with five different receptors of the TNF-R family; however, only receptors DR4 and DR5 are able to induce apoptosis. Interestingly, it has been shown that the expression levels of DR4 and/or DR5 were up-regulated in cancer cells in response to a number of chemotherapeutic drugs (6) . The existence of certain cancer cells only responding to DR4-mediated apoptosis (20) and favorable results obtained with agonistic anti-DR4 antibodies (23) have encouraged the search for DR4-selective TRAIL variants. Recently, Kelley et al. (32) described the use of phage display to select DR4-selective TRAIL variants from a saturation mutagenesis library. However, subsequent analysis revealed that this DR4-selective TRAIL variant containing six mutations was biologically inactive (22) . Activity of this mutant could be restored after reverting one of the mutations back to the wild-type amino acid, but how it affected receptor selectivity was not examined (22) .
Computational protein design methods have been demonstrated by us and others to represent a valuable tool for the improvement and modification of protein-protein interactions (1-4, 20, 34) . From a practical point of view, computational design algorithms enable the modification of several key properties of proteins in a much shorter time frame than any other protein engineering methodologies, such as directed evolution methods.
Previously we used computational protein design to construct a DR5-selective TRAIL variant (20) . This stimulated us to design a DR4-selective TRAIL variant using computational protein design despite the lack of a crystal structure for this receptor. In this study we focused on Asp-218 predicted by the FoldX algorithm to be important for selectivity toward the DR4 receptor. Interestingly, this residue has not been identified before with the phage display approach of Kelley et al. (32) .
From the crystal structure of the TRAIL-DR5 complex and the model of the TRAIL-DR4 complex, it can be observed that Asp-218 forms a hydrogen bond with His-106 of DR5, whereas no hydrogen bond interaction is possible with the equivalent Ala-157 of DR4 (Fig. 7) . When mutating Asp-218 to His or Tyr, the hydrogen bond with His-106 of DR5 is disrupted. In addition, changing Asp-218 into His creates some electrostatic repulsion in this pocket because of two positively charged amino acids in close proximity. In case of the D218Y variant, the substitution of Asp-218 to Tyr introduces van der Waals clashes with His-106 of DR5, forcing one of these residues to be re-accommodated by pushing away the other residue and causing instability to this interaction pocket. Both mutations thus seem to reduce the affinity for DR5.
The DR4 model was built by assuming an identical backbone structure as DR5, as has also been assumed for our 218 mutants in comparison with TRAIL WT. Although this will be true in general, there could be some cases in which small changes in the backbone could affect the predictions. The calculated ⌬⌬G for the complex of D218Y with DR4 is mainly a consequence of the hydrogen bond that was predicted to be formed between Tyr-218 and DR4 Asn-156. A small change in the modeled coordinates of DR4 would preclude formation of such a hydrogen bond, and such an effect may explain why we could not obtain experimental evidence for an increased DR4 affinity for D218Y. The backbone change is more likely to occur in the coordinates of DR4 than of TRAIL, not only because the many deviations from the DR5 sequence in DR4 but also because the single Asp-218 to Tyr mutation does not introduce any clashes with the TRAIL backbone or neighboring TRAIL residues warranting a potential move. In addition, FoldX correctly predicted a decrease in affinity of D218H and D218Y for DR5.
Both the SPR receptor binding data and the biological activity data indicated that D218Y and D218H variants induce apoptosis preferentially via DR4 and thus are DR4-selective. Receptor binding experiments using SPR showed unchanged affinity for the variants D218H and D218Y toward the DR4-Ig receptor and an increased dissociation rate to DR5-Ig when compared with rhTRAIL WT, resulting in a reduced binding affinity to this receptor. Binding of D218H and D218Y toward the decoy receptors DcR2-Ig, OPG-Ig, and, although less pronounced, to DcR1-Ig also showed a significant reduction in binding affinity when compared with rhTRAIL WT.
In summary, computational protein design can be successfully used to direct TRAIL variants to either the DR5 (20) or DR4 receptor. The computational method used in our study is based on general applicable principles, and it can be used on any other protein as template structure, spanning the whole sequence and structure space of protein families and protein folds. This was convincingly demonstrated in other protein design works using FoldX (2, 20, 29, 30, (35) (36) (37) (38) . The design predictions for DR4-selective rhTRAIL variants resulted in variants that do show agonistic DR4 specificity in cell line assays. Analytical SPR receptor binding tests showed a lowered DR5 affinity in concert with increased DR4 specificity. These results combined show that the variants D218H and D218Y have become DR4-selective.
